Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease.
BACKGROUND: A major clinical feature in multiple myeloma is the development of osteolytic bone disease. The increase in bone destruction is due to uncontrolled osteoclastic bone resorption. Until recently the factors responsible for mediating the increase in osteoclast formation in myeloma have been unclear. However, recent studies have implicated a number of factors, including the ligand for receptor activator of NFkappaB (RANKL) and macrophage inflammatory protein-1alpha. The demonstration...Expand abstract
- Publication status:
- Publisher copy:
- Copyright date: